{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:35:38Z","timestamp":1789932938377,"version":"4.0.1"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2017,7,15]]},"abstract":"<jats:p>High\u2010risk Human papilloma virus (HPV) types are the causative agents of cervical cancer and several other anogenital malignancies. The viral proteins expressed in the (pre)malignant cells are considered ideal targets for immunological intervention. Many approaches have been evaluated for this purpose, mostly aiming at the induction of HPV16 E7\u2010 and\/or E6\u2010specific cellular immunogenicity. As clinical success has so far been limited, novel approaches are required. We describe the development and pre\u2010clinical testing of a vaccine candidate consisting of replication\u2010deficient adenovirus type 26 and 35 based vectors for the interception of HPV16\u2010 and HPV18\u2010related disease. We developed HPV16\u2010 and HPV18\u2010specific antigens consisting of fusion proteins of E2, E6 and E7. The vaccine will be suitable for every disease stage, from incident and persistent infections where E2 is predominantly expressed up to late stages where E6 and E7 expression are upregulated. Importantly E6 and E7 are present as reordered fragments to abrogate the transforming activity of these two proteins. Loss of transforming activity was demonstrated in different <jats:italic>in vitro<\/jats:italic> models. Robust T\u2010cell immunogenicity was induced upon immunization of mice with the vaccine candidate. Finally, the developed vaccine vectors showed considerable therapeutic efficacy in the TC\u20101 mouse model. The absence of transforming activity of the antigens and the favorable immunogenicity profile of the adenovirus based vectors along with the fact that these vectors can be readily produced on a large scale makes this approach attractive for clinical evaluation.<\/jats:p>","DOI":"10.1002\/ijc.30679","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T16:12:58Z","timestamp":1488816778000},"page":"393-404","source":"Crossref","is-referenced-by-count":27,"title":["Development of a replication\u2010deficient adenoviral vector\u2010based vaccine candidate for the interception of HPV16\u2010 and HPV18\u2010induced infections and disease"],"prefix":"10.1002","volume":"141","author":[{"given":"Selina","family":"Khan","sequence":"first","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Oosterhuis","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Wunderlich","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien M.","family":"Bunnik","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bhaggoe","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Boedhoe","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santusha","family":"Karia","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske D.M.","family":"Steenbergen","sequence":"additional","affiliation":[{"name":"Department of Pathology VU University Medical Center Amsterdam  The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leontien","family":"Bosch","sequence":"additional","affiliation":[{"name":"Department of Pathology VU University Medical Center Amsterdam  The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Janssen","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jort","family":"Vellinga","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Scheper","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7151-8654","authenticated-orcid":false,"given":"Jerome","family":"Custers","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Preventions BV  CA Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27485"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24215"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.037"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181a388c4"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0831"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0994"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002756"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6317"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00239-1"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-81-7-1825"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.5.3925-3934.1998"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025981"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.16.7583-7591.2001"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.013"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02696-06"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.101"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.12.061"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25894"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btg247"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2008.05.001"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.06.006"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.21.11451-11460.2004"},{"key":"e_1_2_7_25_1","first-page":"381","article-title":"Transformation assays for HPV oncoproteins","volume":"119","author":"Massimi P","year":"2005","journal-title":"Methods Mol Med"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.65.9.4860-4866.1991"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.63.10.4417-4421.1989"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-302"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.10.049"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.350"},{"key":"e_1_2_7_31_1","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin KY","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2005.37.1.63"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1423-0127-17-88"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature18300"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02859-13"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.6141-6146.1999"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-015-0025-y"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00558-3"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200910-1484OC"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.007"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.30679","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.30679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:21:16Z","timestamp":1695550876000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.30679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,7,15]]}},"alternative-id":["10.1002\/ijc.30679"],"URL":"https:\/\/doi.org\/10.1002\/ijc.30679","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,24]]}}}